Skip to content

Qyuns Therapeutics Co., Ltd.

Request correction

Corporate brand

Unclaimed

Qyuns Therapeutics (2509.HK) is a China-based biopharmaceutical company focused on antibody therapies for autoimmune and allergic diseases.

Last updated September 16, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Qyuns Therapeutics (2509.HK) was founded in 2015 and focuses on antibody drug solutions for autoimmune and allergic diseases. The company states it has a fully self-developed drug pipeline and commercial-scale in-house manufacturing capability, with an integrated layout spanning antibody discovery, preclinical research, regulatory filing, clinical development, large-scale production and commercialization. Its pipeline covers dermatology, rheumatology, respiratory and digestive disease areas, and it pursues diversified strategic collaborations with pharmaceutical partners.

History

Qyuns Therapeutics (2509.HK) was founded in 2015. The company describes itself as a clinical-stage biopharmaceutical enterprise focused on biologic therapies for autoimmune and allergic diseases, with a fully self-developed drug pipeline and commercial-scale in-house manufacturing capability. It states it has achieved full-industry-chain integration from antibody discovery, preclinical research, regulatory filing and clinical development to large-scale production and commercialization. Its pipeline spans dermatology, rheumatology, respiratory and digestive areas. According to its corporate history, QX001S (赛乐信®) was successfully launched in 2024, and the company was successfully listed on the Main Board of the Hong Kong Stock Exchange.

Products and positioning

Focused on antibody drug solutions for autoimmune and allergic diseases, aiming to address drug accessibility and affordability.

  • QX001S

    Qyuns' expected first commercialized drug, potentially the first approved ustekinumab biosimilar in China.

  • QX005N

    A recombinant humanized anti-IL-4Rα monoclonal antibody and one of Qyuns' core products.

  • QX002N

    A high-affinity monoclonal antibody targeting IL-17A and one of Qyuns' core products.

  • QX004N

    An IL-23p19 inhibitor being developed for psoriasis and Crohn's disease.

  • QX008N

    A recombinant humanized anti-TSLP monoclonal antibody injection for asthma and moderate-to-severe COPD.

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/qyuns-therapeutics-co-ltd-china · Editorial policy · How profiles are compiled